{"id":464888,"date":"2024-10-20T10:37:29","date_gmt":"2024-10-20T10:37:29","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/bs-iso-59102024-2\/"},"modified":"2024-10-26T19:35:49","modified_gmt":"2024-10-26T19:35:49","slug":"bs-iso-59102024-2","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/bsi\/bs-iso-59102024-2\/","title":{"rendered":"BS ISO 5910:2024"},"content":{"rendered":"
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
2<\/td>\n | undefined <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
9<\/td>\n | 1 Scope 2 Normative references <\/td>\n<\/tr>\n | ||||||
10<\/td>\n | 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 4 Abbreviated terms <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 5 Fundamental requirements 5.1 General 5.2 Risk management 6 Device design 6.1 Intended use and indication for use 6.2 Design inputs 6.2.1 General 6.2.2 Operational specifications <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 6.2.3 Functional, performance and safety requirements <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 6.2.4 Usability 6.2.5 Packaging, labelling and sterilization 6.3 Design outputs 6.4 Design transfer (manufacturing verification and validation) <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 7 Design verification testing and analysis, and design validation 7.1 General requirements 7.2 In vitro assessment 7.2.1 General 7.2.2 Test articles, sample selection, test conditions and reporting requirements <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | 7.2.3 Device material property assessment <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | 7.2.4 Device durability assessment 7.2.5 Device corrosion assessment 7.2.6 Design specific testing 7.2.7 Visibility <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | 7.2.8 Simulated use assessment 7.2.9 Human factors and usability assessment 7.2.10 Device MRI safety 7.3 Preclinical in vivo evaluation 7.3.1 General 7.3.2 Overall requirements <\/td>\n<\/tr>\n | ||||||
28<\/td>\n | 7.3.3 Methods <\/td>\n<\/tr>\n | ||||||
29<\/td>\n | 7.3.4 Test report <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | 7.4 Clinical investigations 7.4.1 General 7.4.2 Study considerations <\/td>\n<\/tr>\n | ||||||
32<\/td>\n | 7.4.3 Study end points <\/td>\n<\/tr>\n | ||||||
33<\/td>\n | 7.4.4 Ethical considerations 7.4.5 Distribution of subjects and investigators <\/td>\n<\/tr>\n | ||||||
34<\/td>\n | 7.4.6 Statistical considerations including sample size and duration <\/td>\n<\/tr>\n | ||||||
35<\/td>\n | 7.4.7 Patient selection criteria <\/td>\n<\/tr>\n | ||||||
36<\/td>\n | 7.4.8 Clinical data requirements <\/td>\n<\/tr>\n | ||||||
39<\/td>\n | 7.4.9 Clinical investigation analysis and reporting 7.4.10 Post-market clinical follow-up <\/td>\n<\/tr>\n | ||||||
40<\/td>\n | 8 Manufacturing verification and validation <\/td>\n<\/tr>\n | ||||||
41<\/td>\n | Annex A (informative) Rationale for the provisions of this document <\/td>\n<\/tr>\n | ||||||
44<\/td>\n | Annex B (informative) Types and examples of heart valve repair devices and delivery systems <\/td>\n<\/tr>\n | ||||||
51<\/td>\n | Annex C (normative) Packaging <\/td>\n<\/tr>\n | ||||||
52<\/td>\n | Annex D (normative) Product labels, instructions for use and training <\/td>\n<\/tr>\n | ||||||
55<\/td>\n | Annex E (normative) Sterilization <\/td>\n<\/tr>\n | ||||||
56<\/td>\n | Annex F (informative) Heart valve repair system characteristics <\/td>\n<\/tr>\n | ||||||
58<\/td>\n | Annex G (informative) Example of a transcatheter heart valve repair system hazard analysis <\/td>\n<\/tr>\n | ||||||
59<\/td>\n | Annex H (informative) In vitro test guidelines for paediatric devices <\/td>\n<\/tr>\n | ||||||
62<\/td>\n | Annex I (informative) Identification of boundary conditions <\/td>\n<\/tr>\n | ||||||
66<\/td>\n | Annex J (informative) Test platforms for in vitro testing <\/td>\n<\/tr>\n | ||||||
68<\/td>\n | Annex K (informative) Considerations for device material properties undergoing alterations post implantation <\/td>\n<\/tr>\n | ||||||
69<\/td>\n | Annex L (informative) Corrosion assessment <\/td>\n<\/tr>\n | ||||||
72<\/td>\n | Annex M (informative) Durability assessment <\/td>\n<\/tr>\n | ||||||
79<\/td>\n | Annex N (informative) Additional device design evaluation considerations <\/td>\n<\/tr>\n | ||||||
82<\/td>\n | Annex O (normative) Delivery system design evaluation <\/td>\n<\/tr>\n | ||||||
84<\/td>\n | Annex P (informative) Preclinical ex vivo and in vivo evaluations <\/td>\n<\/tr>\n | ||||||
88<\/td>\n | Annex Q (normative) Adverse event classification during clinical investigation <\/td>\n<\/tr>\n | ||||||
94<\/td>\n | Annex R (informative) Multimodality imaging of TAVr, TMVr and TTVr (pre-, peri- and post-implantation) <\/td>\n<\/tr>\n | ||||||
99<\/td>\n | Annex S (informative) Clinical investigation end points for valve repair devices: Suggestions for end points and their timing <\/td>\n<\/tr>\n | ||||||
103<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" Cardiovascular implants and extracorporeal systems. Cardiac valve repair devices<\/b><\/p>\n |